ReviewJournal of molecular histology2025
The role of the CXC chemokine family in endometriosis research and its therapeutic potential.
Review in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Endometriosis (EM) is a chronic estrogen-dependent gynecological disease that affects approximately 10% of women of reproductive age and is a leading cause of infertility worldwide. In addition to reproductive dysfunction, EM is associated with chronic pain, psychological distress, and significant healthcare costs, yet its etiopathogenesis remains incompletely understood. Chemokines, especially members of the CXC family, have attracted increasing attention for their roles in EM-related inflammation, immune dysregulation, cell migration, angiogenesis, and pain modulation. These small signaling proteins, typically 8-10 kDa in size, are aberrantly expressed in ectopic lesions and participate in both disease initiation and progression. This review aims to systematically summarize current research on the expression patterns and biological functions of CXC chemokines in EM, with a particular focus on their contributions to diagnostic strategies, pathological mechanisms, and therapeutic development. While emerging evidence highlights their importance, further studies are needed to clarify subtype-specific mechanisms and clinical applicability. Understanding the roles of CXC chemokines may help uncover novel molecular targets for diagnosis and intervention, thereby advancing more effective and personalized treatments for patients with endometriosis.
Indexed as
Identifiers
40580368What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.